CY1116019T1 - Μεθοδος χρησης καταστολεων histone deacetylase και παρακολουθηση παραγοντων βιο-σημανσης σε θεραπεια συνδυασμου - Google Patents
Μεθοδος χρησης καταστολεων histone deacetylase και παρακολουθηση παραγοντων βιο-σημανσης σε θεραπεια συνδυασμουInfo
- Publication number
- CY1116019T1 CY1116019T1 CY20151100112T CY151100112T CY1116019T1 CY 1116019 T1 CY1116019 T1 CY 1116019T1 CY 20151100112 T CY20151100112 T CY 20151100112T CY 151100112 T CY151100112 T CY 151100112T CY 1116019 T1 CY1116019 T1 CY 1116019T1
- Authority
- CY
- Cyprus
- Prior art keywords
- histone deacetylase
- combination therapy
- methods
- bio
- monitoring
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/166—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/164—Amides, e.g. hydroxamic acids of a carboxylic acid with an aminoalcohol, e.g. ceramides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
- A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4525—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Abstract
Στην παρούσα παρέχονται μέθοδοι για την χρήση τουλάχιστον ενός καταστολέα histone deacetylase για την μείωση της δραστικότητας επισκευής κυτταρικού DNA, μέθοδοι για την παρακολούθηση της μείωσης της δραστικότητας επισκευής κυτταρικού DNA χρησιμοποιώντας τουλάχιστον ένα παράγοντα βίο-σήμανσης, μέθοδοι για την θεραπεία του καρκίνου με χρήση τουλάχιστον ενός καταστολέα histone deacetylase για την μείωση της δραστικότητας επισκευής κυτταρικού DNA σε θεραπεία συνδυασμού, μέθοδοι θεραπείας συνδυασμού όπου ο τουλάχιστον ένας καταστολέας histone deacetylase επεμβαίνει σε ένα μηχανισμό επισκευής DNA που εμπλέκει RAD51, μέθοδοι για την πρόβλεψη μιας χρονικής περιόδου επαγωγής μεταξύ μιας πρώτης χορήγησης του τουλάχιστον ενός καταστολέα histone deacetylase και μιας δεύτερης χορήγησης τουλάχιστον μιας άλλης θεραπευτικής αγωγής, και φαρμακευτικές συνθέσεις για θεραπεία συνδυασμού.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US87190006P | 2006-12-26 | 2006-12-26 | |
EP07869059.1A EP2099442B1 (en) | 2006-12-26 | 2007-12-07 | Method of using histone deacetylase inhibitors and monitoring biomarkers in combination therapy |
Publications (1)
Publication Number | Publication Date |
---|---|
CY1116019T1 true CY1116019T1 (el) | 2017-01-25 |
Family
ID=39588962
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CY20151100112T CY1116019T1 (el) | 2006-12-26 | 2015-02-02 | Μεθοδος χρησης καταστολεων histone deacetylase και παρακολουθηση παραγοντων βιο-σημανσης σε θεραπεια συνδυασμου |
Country Status (17)
Country | Link |
---|---|
US (1) | US9408816B2 (el) |
EP (2) | EP2099442B1 (el) |
JP (2) | JP2010514777A (el) |
KR (2) | KR20120090100A (el) |
CN (1) | CN101674820B (el) |
AU (1) | AU2007340129B2 (el) |
CA (1) | CA2674084C (el) |
CY (1) | CY1116019T1 (el) |
DK (1) | DK2099442T3 (el) |
ES (1) | ES2529147T3 (el) |
NZ (1) | NZ578428A (el) |
PL (1) | PL2099442T3 (el) |
PT (1) | PT2099442E (el) |
RU (2) | RU2446796C2 (el) |
SI (1) | SI2099442T1 (el) |
WO (1) | WO2008082856A1 (el) |
ZA (1) | ZA200905060B (el) |
Families Citing this family (41)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BRPI0409227C1 (pt) | 2003-04-07 | 2021-05-25 | Axys Pharm Inc | composto, composição farmacêutica, uso de um composto e processo para a preparação de um composto de fórmula (i) |
PT2099442E (pt) | 2006-12-26 | 2015-02-10 | Pharmacyclics Inc | Métodos de utilização de inibidores de histona desacetilase e monitorização de biomarcadores em terapia de combinação |
EP2156370B1 (en) | 2007-05-14 | 2011-10-12 | Historx, Inc. | Compartment segregation by pixel characterization using image data clustering |
ES2599902T3 (es) * | 2007-06-15 | 2017-02-06 | Novartis Ag | Sistema y método de microscopio para obtener datos de muestra normalizados |
CA2604317C (en) | 2007-08-06 | 2017-02-28 | Historx, Inc. | Methods and system for validating sample images for quantitative immunoassays |
CA2596204C (en) * | 2007-08-07 | 2019-02-26 | Historx, Inc. | Method and system for determining an optimal dilution of a reagent |
US7978258B2 (en) * | 2007-08-31 | 2011-07-12 | Historx, Inc. | Automatic exposure time selection for imaging tissue |
JP2011524743A (ja) * | 2008-06-02 | 2011-09-08 | アンスティテュ・グスターブ・ルシ | ナチュラルキラーp30(NKp30)機能障害及びその生物学的用途 |
US9240043B2 (en) | 2008-09-16 | 2016-01-19 | Novartis Ag | Reproducible quantification of biomarker expression |
WO2010114805A1 (en) * | 2009-03-31 | 2010-10-07 | The Trustees Of The University Of Pennsylvania | Methods of treating cancer with phenformin |
US8603521B2 (en) | 2009-04-17 | 2013-12-10 | Pharmacyclics, Inc. | Formulations of histone deacetylase inhibitor and uses thereof |
WO2011056542A1 (en) * | 2009-10-26 | 2011-05-12 | Ramot At Tel-Aviv University Ltd. | Cancer therapy with combinations of fts with hdac inhibitors |
EP2322658A1 (en) | 2009-11-13 | 2011-05-18 | Centre National de la Recherche Scientifique (CNRS) | Signature for the diagnosis of breast cancer aggressiveness and genetic instability |
WO2011103563A1 (en) * | 2010-02-22 | 2011-08-25 | Arno Therapeutics, Inc | Methods and compositions for inhibiting and preventing the growth of malignant mast cells |
WO2011153514A2 (en) | 2010-06-03 | 2011-12-08 | Pharmacyclics, Inc. | The use of inhibitors of bruton's tyrosine kinase (btk) |
CN103827314A (zh) | 2011-05-18 | 2014-05-28 | 国家科学研究中心 | 用于诊断癌侵袭性和遗传不稳定性的标记 |
RU2644635C2 (ru) * | 2011-07-07 | 2018-02-13 | Рисёрч Кансер Инститьют Оф Америка | Системы, способы и составы для лечения рака |
US8933078B2 (en) | 2011-07-14 | 2015-01-13 | Research Cancer Institute Of America | Method of treating cancer with combinations of histone deacetylase inhibitors (HDAC1) substances |
SG2014014419A (en) * | 2011-09-13 | 2014-07-30 | Pharmacyclics Inc | Formulations of histone deacetylase inhibitor in combination with bendamustine and uses thereof |
WO2013102680A1 (en) | 2012-01-05 | 2013-07-11 | Centre National De La Recherche Scientifique (Cnrs) | Signature for the diagnosis of lung cancer aggressiveness and genetic instability |
WO2013153532A1 (en) | 2012-04-12 | 2013-10-17 | University Of Saskatchewan | Phthalocyanine compounds useful as reca inhibitors and methods of using same |
JP6575950B2 (ja) | 2012-07-24 | 2019-09-18 | ファーマサイクリックス エルエルシー | Bruton型チロシンキナーゼ(Btk)阻害剤に対する耐性を伴う変異 |
CN103191412B (zh) * | 2013-04-01 | 2019-08-02 | 北京师范大学 | Pa200和乙酰化介导核心组蛋白通过蛋白酶体降解 |
CN103324846A (zh) * | 2013-06-13 | 2013-09-25 | 浙江加州国际纳米技术研究院绍兴分院 | 结直肠癌症治疗预后生物标记物的筛选方法 |
CN103310105A (zh) * | 2013-06-13 | 2013-09-18 | 浙江加州国际纳米技术研究院绍兴分院 | 筛选非小细胞肺癌治疗疗效生物标记物的方法 |
JP6800750B2 (ja) | 2013-08-02 | 2020-12-16 | ファーマサイクリックス エルエルシー | 固形腫瘍の処置方法 |
US9885086B2 (en) | 2014-03-20 | 2018-02-06 | Pharmacyclics Llc | Phospholipase C gamma 2 and resistance associated mutations |
RU2593342C1 (ru) * | 2015-03-26 | 2016-08-10 | Федеральное государственное бюджетное научное учреждение "Томский научно-исследовательский институт онкологии" (Томский НИИ онкологии) | Способ комбинированного лечения немелкоклеточного рака легкого 1в-111 стадии с персонификацией адъювантной химиотерапии |
US10973819B2 (en) | 2016-03-02 | 2021-04-13 | The University Of Chicago | Small molecules inhibitors of RAD51 |
KR20180126085A (ko) * | 2016-05-05 | 2018-11-26 | 난토믹스, 엘엘씨 | 체크포인트 부전 및 그 방법(checkpoint failure and methods therefor) |
MX2018014366A (es) | 2016-05-27 | 2019-04-11 | Synthex Inc | Interfaces de proteina. |
US11890292B2 (en) | 2017-02-27 | 2024-02-06 | Research Cancer Institute Of America | Compositions, methods, systems and/or kits for preventing and/or treating neoplasms |
US11369585B2 (en) | 2017-03-17 | 2022-06-28 | Research Cancer Institute Of America | Compositions, methods, systems and/or kits for preventing and/or treating neoplasms |
ES2925218T3 (es) | 2017-09-11 | 2022-10-14 | Cyteir Therapeutics Inc | Inhibidores de RAD51 |
GB2584210B (en) | 2017-11-22 | 2022-03-16 | Synthex Inc | Peptides for inhibiting RAD51 |
KR102236356B1 (ko) * | 2017-11-24 | 2021-04-05 | 주식회사 종근당 | 루푸스의 예방 또는 치료를 위한 조성물 |
KR20190118251A (ko) * | 2018-04-10 | 2019-10-18 | 주식회사 종근당 | 건성안의 예방 또는 치료를 위한 조성물 |
CN109490543B (zh) * | 2018-11-26 | 2021-08-31 | 复旦大学附属金山医院 | 一种预测胃肠间质瘤耐药性的试剂盒及其应用 |
GB201918413D0 (en) * | 2019-12-13 | 2020-01-29 | Z Factor Ltd | Compounds and their use for the treatment of alpha1-antitrypsin deficiency |
CN112485233B (zh) * | 2020-11-03 | 2022-08-26 | 山东师范大学 | 一种检测去乙酰化酶用纳米传感器及其检测方法和应用 |
CN116196314B (zh) * | 2023-05-04 | 2023-08-15 | 广州市妇女儿童医疗中心 | Ri-1或其盐在制备防治胃肠道疾病的药物中的应用 |
Family Cites Families (94)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3126375A (en) | 1964-03-24 | Chioacyl | ||
US2789118A (en) | 1956-03-30 | 1957-04-16 | American Cyanamid Co | 16-alpha oxy-belta1, 4-pregnadienes |
US2990401A (en) | 1958-06-18 | 1961-06-27 | American Cyanamid Co | 11-substituted 16alpha, 17alpha-substituted methylenedioxy steroids |
US3048581A (en) | 1960-04-25 | 1962-08-07 | Olin Mathieson | Acetals and ketals of 16, 17-dihydroxy steroids |
US3749712A (en) | 1970-09-25 | 1973-07-31 | Sigma Tau Ind Farmaceuti | Triamcinolone acetonide esters and process for their preparation |
BE794063A (fr) | 1972-01-17 | 1973-07-16 | Henkel & Cie Gmbh | Anti-inflammatoires pour compositions cosmetiques |
US3996359A (en) | 1972-05-19 | 1976-12-07 | Ab Bofors | Novel stereoisomeric component A of stereoisomeric mixtures of 2'-unsymmetrical 16,17-methylenedioxy steroid 21-acylates, compositions thereof, and method of treating therewith |
SE378110B (el) | 1972-05-19 | 1975-08-18 | Bofors Ab | |
SE378109B (el) | 1972-05-19 | 1975-08-18 | Bofors Ab | |
US3775656A (en) * | 1972-05-22 | 1973-11-27 | Aviat Inc | Platform stabilization system |
CH581818A5 (el) * | 1973-02-27 | 1976-11-15 | Cierva Juan J De | |
EP0084236A3 (en) | 1981-12-22 | 1983-08-03 | Fbc Limited | Fungicidal heterocyclic compounds and compositions containing them |
US4498038A (en) * | 1983-02-15 | 1985-02-05 | Malueg Richard M | Stabilization system for soft-mounted platform |
GB8518301D0 (en) | 1985-07-19 | 1985-08-29 | Fujisawa Pharmaceutical Co | Hydrodynamically explosive systems |
EP0230654B1 (en) | 1985-12-28 | 1992-03-18 | Sumitomo Pharmaceuticals Company, Limited | Sustained pulsewise release pharmaceutical preparation |
US4885314A (en) | 1987-06-29 | 1989-12-05 | Merck & Co., Inc. | Novel HMG-CoA reductase inhibitors |
US4782084A (en) | 1987-06-29 | 1988-11-01 | Merck & Co., Inc. | HMG-COA reductase inhibitors |
DE3889545T2 (de) * | 1987-10-20 | 1994-10-13 | Otsuka Pharma Co Ltd | Phenylcarbonsäure-abkömmlinge. |
US5612059A (en) | 1988-08-30 | 1997-03-18 | Pfizer Inc. | Use of asymmetric membranes in delivery devices |
JPH03215470A (ja) | 1990-01-22 | 1991-09-20 | Suntory Ltd | プロピオン酸アミド誘導体,その製造法及びそれを有効成分として含有する除草剤 |
US5017381A (en) | 1990-05-02 | 1991-05-21 | Alza Corporation | Multi-unit pulsatile delivery system |
DE4124345A1 (de) * | 1991-07-23 | 1993-01-28 | Gruenenthal Gmbh | Substituierte 3,4-dihydronaphthaline, diese verbindungen enthaltende arzneimittel und verfahren zur herstellung dieser verbindungen und arzneimittel |
US5229135A (en) | 1991-11-22 | 1993-07-20 | Prographarm Laboratories | Sustained release diltiazem formulation |
US5260068A (en) | 1992-05-04 | 1993-11-09 | Anda Sr Pharmaceuticals Inc. | Multiparticulate pulsatile drug delivery system |
US5260069A (en) | 1992-11-27 | 1993-11-09 | Anda Sr Pharmaceuticals Inc. | Pulsatile particles drug delivery system |
DE4327365A1 (de) | 1993-08-14 | 1995-02-16 | Boehringer Mannheim Gmbh | Verwendung von Phenolen und Phenolderivaten als Arzneimittel mit fibrinogensenkender Wirkung |
US5448938A (en) * | 1993-10-18 | 1995-09-12 | Guardian Technologies International, Inc. | Removable ballistic resistant armor seat cover and floor mat |
US5567441A (en) | 1995-03-24 | 1996-10-22 | Andrx Pharmaceuticals Inc. | Diltiazem controlled release formulation |
US5798119A (en) | 1995-06-13 | 1998-08-25 | S. C. Johnson & Son, Inc. | Osmotic-delivery devices having vapor-permeable coatings |
US5837284A (en) | 1995-12-04 | 1998-11-17 | Mehta; Atul M. | Delivery of multiple doses of medications |
US5958957A (en) * | 1996-04-19 | 1999-09-28 | Novo Nordisk A/S | Modulators of molecules with phosphotyrosine recognition units |
ZA98376B (en) | 1997-01-23 | 1998-07-23 | Hoffmann La Roche | Sulfamide-metalloprotease inhibitors |
US5840329A (en) | 1997-05-15 | 1998-11-24 | Bioadvances Llc | Pulsatile drug delivery system |
KR100247563B1 (ko) | 1997-07-16 | 2000-04-01 | 박영구 | 키랄3,4-에폭시부티르산및이의염의제조방법 |
AU766219B2 (en) | 1998-02-02 | 2003-10-09 | 1149336 Ontario Inc. | Method of regulating glucose metabolism, and reagents related thereto |
JP2002506075A (ja) | 1998-03-09 | 2002-02-26 | フォンダテッヒ・ベネルクス・ナムローゼ・フェンノートシャップ | セリンペプチダーゼ調節剤 |
DE19823831A1 (de) | 1998-05-28 | 1999-12-02 | Probiodrug Ges Fuer Arzneim | Neue pharmazeutische Verwendung von Isoleucyl Thiazolidid und seinen Salzen |
DE19828113A1 (de) | 1998-06-24 | 2000-01-05 | Probiodrug Ges Fuer Arzneim | Prodrugs von Inhibitoren der Dipeptidyl Peptidase IV |
DE19828114A1 (de) | 1998-06-24 | 2000-01-27 | Probiodrug Ges Fuer Arzneim | Produgs instabiler Inhibitoren der Dipeptidyl Peptidase IV |
US6211197B1 (en) | 1998-10-07 | 2001-04-03 | Merck Frosst Canada & Co. | Prostaglandin receptor ligands |
GB9904387D0 (en) | 1999-02-25 | 1999-04-21 | Pharmacia & Upjohn Spa | Antitumour synergistic composition |
EP1191861A4 (en) * | 1999-05-28 | 2006-12-06 | David E Grober | AUTONOMOUS, SELF-LEVELING AND SELF-CORRECTIVE STABILIZING PLATFORM |
US6718130B2 (en) * | 1999-05-28 | 2004-04-06 | David E. Grober | Stabilized camera and marker buoy for media coverage of aquatic events |
JP2003506100A (ja) * | 1999-08-10 | 2003-02-18 | パンジーン・コーポレイション | Rad51関連分子および方法を用いる癌治療および診断 |
WO2001014331A2 (en) | 1999-08-24 | 2001-03-01 | Regents Of The University Of California | Non-quinoline inhibitors of malaria parasites |
IL148718A0 (en) * | 1999-09-17 | 2002-09-12 | Abbott Gmbh & Co Kg | Pyrazolopyrimidines as therapeutic agents |
US6921763B2 (en) * | 1999-09-17 | 2005-07-26 | Abbott Laboratories | Pyrazolopyrimidines as therapeutic agents |
DK1233958T3 (da) | 1999-11-23 | 2011-10-17 | Methylgene Inc | Hæmmere af histondeacetylase |
GB0023983D0 (en) * | 2000-09-29 | 2000-11-15 | Prolifix Ltd | Therapeutic compounds |
WO2002030879A2 (en) * | 2000-09-29 | 2002-04-18 | Prolifix Limited | Carbamic acid compounds comprising a sulfonamide linkage as hdac inhibitors |
ES2318649T3 (es) * | 2000-10-20 | 2009-05-01 | EISAI R&D MANAGEMENT CO., LTD. | Procedimiento de preparacion de derivados de 4-fenoxi quinolinas. |
WO2002053775A2 (en) | 2000-12-28 | 2002-07-11 | Epidauros Biotechnologie Ag | Identification of genetic determinants of polymorphic cyp3a5 expression |
MXPA01013172A (es) * | 2001-02-14 | 2002-08-21 | Warner Lambert Co | Inhibidores sulfonamida de metaloproteinasa de matriz. |
MXPA03008560A (es) * | 2001-03-22 | 2004-06-30 | Abbot Gmbh & Co Kg | Pirazolopirimidinas como agentes terapeuticos. |
WO2002083139A1 (en) | 2001-04-10 | 2002-10-24 | Merck & Co., Inc. | Inhibitors of akt activity |
WO2002083140A1 (en) | 2001-04-10 | 2002-10-24 | Merck & Co., Inc. | Inhibitors of akt activity |
WO2002083675A2 (en) | 2001-04-10 | 2002-10-24 | Merck Sharp & Dohme Limited | Inhibitors of akt activity |
WO2002083138A1 (en) | 2001-04-10 | 2002-10-24 | Merck & Co., Inc. | Inhibitors of akt activity |
PL206069B1 (pl) * | 2001-06-28 | 2010-06-30 | Ucb Farchim Sa | Tabletka dwuwarstwowa zawierająca cetyryzynę i pseudoefedrynę |
US7247426B2 (en) * | 2001-08-02 | 2007-07-24 | Agilent Technologies, Inc. | Classifying cancers |
ITMI20011733A1 (it) * | 2001-08-07 | 2003-02-07 | Italfarmaco Spa | Derivati dell'acido idrossamico inibitori degli enzimi istone deacetilasi, quali nuovi farmaci antiinfiammatori inibenti la sintesi di citoc |
RU2298414C2 (ru) | 2001-08-21 | 2007-05-10 | Астеллас Фарма Инк. | Медицинское применение ингибитора гистоновой дезацетилазы и способ оценки его противоопухолевого действия |
US20030166026A1 (en) * | 2002-01-09 | 2003-09-04 | Lynx Therapeutics, Inc. | Identification of specific biomarkers for breast cancer cells |
EP1472379A1 (en) | 2002-02-04 | 2004-11-03 | Epidauros Biotechnologie AG | Polymorphisms in the human gene for tpmt and their use in diagnostic and therapeutic applications |
WO2003070691A1 (fr) | 2002-02-21 | 2003-08-28 | Osaka Industrial Promotion Organization | Derive de n-hydroxycarboxamide |
US20040132825A1 (en) | 2002-03-04 | 2004-07-08 | Bacopoulos Nicholas G. | Methods of treating cancer with HDAC inhibitors |
JP4394960B2 (ja) | 2002-04-08 | 2010-01-06 | メルク エンド カムパニー インコーポレーテッド | Akt活性阻害薬 |
WO2003086404A1 (en) | 2002-04-08 | 2003-10-23 | Merck & Co., Inc. | Fused quinoxaline derivatives as inhibitors of akt activity |
AU2003226250B2 (en) | 2002-04-08 | 2007-08-16 | Merck Sharp & Dohme Corp. | Inhibitors of Akt activity |
US20050130977A1 (en) | 2002-04-08 | 2005-06-16 | Lindsley Craig W. | Inhibitors of akt activity |
KR20050034732A (ko) | 2002-08-02 | 2005-04-14 | 아젠터 디스커버리 리미티드 | 히스톤 디아세틸라제 억제제로서의 치환된티에닐-히드록사믹산 |
EP1400806A1 (en) | 2002-09-18 | 2004-03-24 | G2M Cancer Drugs AG | The use of molecular markers for the preclinical and clinical profiling of inhibitors of enzymes having histone deacetylase activity |
US6769347B1 (en) * | 2002-11-26 | 2004-08-03 | Recon/Optical, Inc. | Dual elevation weapon station and method of use |
JPWO2004074478A1 (ja) | 2003-02-19 | 2006-06-01 | アステラス製薬株式会社 | ヒストンデアセチラーゼ阻害剤の抗腫瘍効果の予測方法 |
BRPI0409227C1 (pt) * | 2003-04-07 | 2021-05-25 | Axys Pharm Inc | composto, composição farmacêutica, uso de um composto e processo para a preparação de um composto de fórmula (i) |
CN1768031A (zh) * | 2003-04-07 | 2006-05-03 | Axys药物公司 | 作为治疗剂的异羟肟酸酯 |
PE20050206A1 (es) | 2003-05-26 | 2005-03-26 | Schering Ag | Composicion farmaceutica que contiene un inhibidor de histona deacetilasa |
GB0317466D0 (en) * | 2003-07-25 | 2003-08-27 | Univ Sheffield | Use |
EP2263694B1 (en) | 2003-09-25 | 2013-06-12 | Astellas Pharma Inc. | Antitumor agent comprising the histone deacetylase inhibitor FK228 and the topoisomerase II inhibitor doxorubicin |
EP1694866A4 (en) | 2003-12-12 | 2007-12-26 | Bayer Pharmaceuticals Corp | GENE EXPRESSION PROFILES AND METHODS OF USE |
WO2005097770A1 (en) | 2004-04-07 | 2005-10-20 | Pharmacyclics, Inc. | Novel hydroxamates as therapeutic agents |
SI1591109T1 (sl) | 2004-04-30 | 2008-10-31 | Topotarget Germany Ag | Formulacija, ki obsega inhibitor histon-deacetilaze in izkazuje dvofazno sproščanje |
CA2569277A1 (en) | 2004-06-04 | 2005-12-15 | Pfizer Products Inc. | Method for treating abnormal cell growth |
RU2271824C1 (ru) * | 2004-08-18 | 2006-03-20 | Ростовский научно-исследовательский онкологический институт МЗ РФ | Способ лечения рака легкого |
WO2006042035A2 (en) * | 2004-10-07 | 2006-04-20 | Pharmacyclics, Inc. | Method of monitoring anti-tumor activity of an hdac inhibitor |
WO2006101454A1 (en) * | 2005-03-21 | 2006-09-28 | S*Bio Pte Ltd | Benzothiophene derivatives: preparation and pharmaceutical applications |
PT2099442E (pt) | 2006-12-26 | 2015-02-10 | Pharmacyclics Inc | Métodos de utilização de inibidores de histona desacetilase e monitorização de biomarcadores em terapia de combinação |
CA2677000A1 (en) | 2007-01-30 | 2008-08-07 | Pharmacyclics, Inc. | Methods for determining cancer resistance to histone deacetylase inhibitors |
EP2060565A1 (en) | 2007-11-16 | 2009-05-20 | 4Sc Ag | Novel bifunctional compounds which inhibit protein kinases and histone deacetylases |
EP2110377A1 (en) | 2008-04-15 | 2009-10-21 | DAC S.r.l. | Spirocyclic derivatives as histone deacetylase inhibitors |
US8603521B2 (en) | 2009-04-17 | 2013-12-10 | Pharmacyclics, Inc. | Formulations of histone deacetylase inhibitor and uses thereof |
UY34295A (es) * | 2011-09-08 | 2013-04-30 | Servier Lab | Nuevo esquema de administración de la n-hidroxi -4- {2-[3- (n,ndimetilaminometil)benzofuran -2- ilcarbonilamino]etoxi}benzamida |
SG2014014419A (en) | 2011-09-13 | 2014-07-30 | Pharmacyclics Inc | Formulations of histone deacetylase inhibitor in combination with bendamustine and uses thereof |
US10078105B2 (en) | 2015-09-23 | 2018-09-18 | Abb Schweiz Ag | Electrical system with arc fault detection |
-
2007
- 2007-12-07 PT PT78690591T patent/PT2099442E/pt unknown
- 2007-12-07 ES ES07869059.1T patent/ES2529147T3/es active Active
- 2007-12-07 US US11/952,985 patent/US9408816B2/en active Active
- 2007-12-07 CA CA2674084A patent/CA2674084C/en not_active Expired - Fee Related
- 2007-12-07 CN CN2007800517726A patent/CN101674820B/zh not_active Expired - Fee Related
- 2007-12-07 DK DK07869059.1T patent/DK2099442T3/en active
- 2007-12-07 KR KR1020127017261A patent/KR20120090100A/ko not_active Application Discontinuation
- 2007-12-07 RU RU2009126655/15A patent/RU2446796C2/ru not_active IP Right Cessation
- 2007-12-07 AU AU2007340129A patent/AU2007340129B2/en not_active Ceased
- 2007-12-07 PL PL07869059T patent/PL2099442T3/pl unknown
- 2007-12-07 EP EP07869059.1A patent/EP2099442B1/en not_active Not-in-force
- 2007-12-07 KR KR1020097015579A patent/KR20090101362A/ko active Application Filing
- 2007-12-07 EP EP13153757.3A patent/EP2626067A1/en not_active Withdrawn
- 2007-12-07 SI SI200731590T patent/SI2099442T1/sl unknown
- 2007-12-07 JP JP2009544149A patent/JP2010514777A/ja active Pending
- 2007-12-07 WO PCT/US2007/086874 patent/WO2008082856A1/en active Application Filing
- 2007-12-09 NZ NZ578428A patent/NZ578428A/en not_active IP Right Cessation
-
2009
- 2009-07-20 ZA ZA200905060A patent/ZA200905060B/xx unknown
-
2011
- 2011-11-29 RU RU2011148293/15A patent/RU2011148293A/ru not_active Application Discontinuation
-
2014
- 2014-02-10 JP JP2014023335A patent/JP5827706B2/ja not_active Expired - Fee Related
-
2015
- 2015-02-02 CY CY20151100112T patent/CY1116019T1/el unknown
Also Published As
Publication number | Publication date |
---|---|
JP2014139181A (ja) | 2014-07-31 |
KR20120090100A (ko) | 2012-08-16 |
US9408816B2 (en) | 2016-08-09 |
CA2674084C (en) | 2013-05-14 |
CA2674084A1 (en) | 2008-07-10 |
RU2446796C2 (ru) | 2012-04-10 |
WO2008082856A1 (en) | 2008-07-10 |
EP2099442A1 (en) | 2009-09-16 |
SI2099442T1 (sl) | 2015-03-31 |
US20080153877A1 (en) | 2008-06-26 |
EP2626067A1 (en) | 2013-08-14 |
RU2009126655A (ru) | 2011-02-10 |
JP2010514777A (ja) | 2010-05-06 |
EP2099442A4 (en) | 2010-06-16 |
KR20090101362A (ko) | 2009-09-25 |
PL2099442T3 (pl) | 2015-04-30 |
JP5827706B2 (ja) | 2015-12-02 |
NZ578428A (en) | 2012-03-30 |
CN101674820A (zh) | 2010-03-17 |
AU2007340129B2 (en) | 2012-02-02 |
ZA200905060B (en) | 2010-07-28 |
PT2099442E (pt) | 2015-02-10 |
ES2529147T3 (es) | 2015-02-17 |
DK2099442T3 (en) | 2015-02-16 |
AU2007340129A1 (en) | 2008-07-10 |
CN101674820B (zh) | 2013-09-25 |
RU2011148293A (ru) | 2013-06-10 |
EP2099442B1 (en) | 2014-11-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CY1116019T1 (el) | Μεθοδος χρησης καταστολεων histone deacetylase και παρακολουθηση παραγοντων βιο-σημανσης σε θεραπεια συνδυασμου | |
CY1120961T1 (el) | Δοσολογικες μορφες απο του στοματος που περιλαμβανουν αντιαιμοπεταλιακο παραγοντα και αναστολεα οξεος | |
CY1121135T1 (el) | Ενωσεις υποκατεστημενης τετρακυκλιnhς για την θεραπευτικη αγωγη φλεγμονωδων διαταραχων του δερματος | |
PH12017500930A1 (en) | Hsp90 inhibitor combinations | |
EA201300171A1 (ru) | Способы и композиции для терапии рака печени | |
UA118645C2 (uk) | Спосіб комбінованої терапії раку наночастинками, що містять рапаміцин і альбумін | |
MX2010007936A (es) | Anticuerpo anti-nr-10 y su uso. | |
CL2011000916A1 (es) | Uso de una combinacion de un inhibidor de proteasoma epoxicetona peptidica o una sal farmaceutica aceptable del mismo, y uno o mas de otros agentes terapeuticos para tratar el cancer. | |
EA200870185A1 (ru) | Комбинации ингибиторов ang2 и vegf | |
AR058182A1 (es) | Metodos, composiciones y equipos par el tratamiento de afecciones medicas | |
CL2008001124A1 (es) | Formulacion farmaceutica que comprende al menos un derivado de acido lipoico y un reactivo formador de par ionico, util en el tratamiento del cancer. | |
BRPI0712607A8 (pt) | métodos de tratamento de acidente vascular cerebral | |
EA201170521A1 (ru) | Новые соединения | |
AU2011328009A8 (en) | Compounds and methods for treating pain | |
CY1123043T1 (el) | Συνδυαστικες θεραπειες για την αγωγη ανθεκτικων στη χημειοθεραπεια καρκινων | |
BR112013019083A2 (pt) | combinação de (a) um imunoconjugado, composição farmacêutica, uso de (a) um imunoconjugado, método de tratamento de uma doença em um individuo, método de estímulo de função celular efetora em um indivíduo e kit destinado ao tratamento de uma doença. | |
EA201100609A1 (ru) | Способы лечения воспаления | |
BRPI0908635A8 (pt) | composto, composição farmacêutica e método de tratamento de câncer | |
BR112015023439A2 (pt) | combinação de tratamentos de câncer utilizando micrornas e inibidores egfr-tki | |
CY1118968T1 (el) | Αυξημενη βιοδιαθεσιμοτητα δραστικης ουσιας σε θεραπεια ναλτρεξονης | |
CY1116216T1 (el) | Μεθοδος θεραπειας ασθενειας αποθηκευσης γλυκογονου | |
MX2015010791A (es) | Metodos para tratar el cancer y prevenir la resistencia a farmacos. | |
BRPI0908168A2 (pt) | composto, medicamento, inibidor de dipeptidil peptidase-iv, agente terapêutico para diabetes, e, método de tratamento de diabetes | |
ES2723827T3 (es) | Terapia de combinación de fármacos para el tratamiento de tumores sólidos | |
EA201170821A1 (ru) | Энзастаурин для лечения рака |